Know Labs, Inc. (KNW) Q3 2024 Earnings Call Transcript Summary
Know Labs, Inc. (KNW) Q3 2024 Earnings Call Transcript Summary
Know Labs has completed the prototype of a new non-invasive glucose monitoring device, KnowU, marking significant progress in hardware development. The KnowU is 85% smaller than its predecessor and designed for continuous, wearable data monitoring.The following is a summary of the Know Labs, Inc. (KNW) Q3 2024 Earnings Call Transcript:
以下是 Know Labs，Inc.（KNW）2024年第三季度業績會全文摘要：
Financial Performance:
金融業績：
Know Labs reported a net loss of $4.1 million for Q3 2024, increasing from the previous year's $3.6 million. However, earnings per share improved, showing a loss of $0.05 compared to a $0.07 loss in Q3 2023.
The net loss included non-cash expenses of $1.58 million, with specific losses from stock-based compensation, amortization of lease rights, and extension of notes.
Know Labs報告2024年第三季度淨虧損410萬美元，較上年同期的360萬美元有所增加。然而，每股收益有所改善，虧損爲0.05美元，而2013年第三季度虧損爲0.07美元。
淨虧損包括158萬美元的非現金費用，其中包括股票獎勵、租賃權攤銷和票據展期等具體損失。
Business Progress:
業務進展：
Know Labs has completed the prototype of a new non-invasive glucose monitoring device, KnowU, marking significant progress in hardware development. The KnowU is 85% smaller than its predecessor and designed for continuous, wearable data monitoring.
Substantial advancements have also been made in clinical trials achieving a mean absolute relative difference (MARD) across various studies averaging around 11%. These trials are crucial for FDA approval and further development of the KnowU device.
The company has successfully expanded its intellectual property portfolio and initiated a global patent licensing program to monetize its technology, reflecting strides in corporate strategy and IP management.
Know Labs已完成一個新的非侵入式葡萄糖監測設備知U的原型，標誌着硬件開發的重大進展。知U比前一代設備小85％，適合連續佩戴數據監測。
在臨床試驗方面取得了實質性進展，各項研究中的平均絕對相對差（MARD）平均約爲11％。這些試驗對於FDA批准和進一步開發KnowU設備至關重要。
公司已成功擴大其知識產權組合，並啓動全球專利許可計劃以實現技術的商業化，這反映了企業戰略和知識產權管理方面的取得的進展。
Opportunities:
機會：
The launch of KnowU presents a significant market opportunity with its non-invasive monitoring technology suitable for continuous use, offering a potential leap in glycemic monitoring for diabetes management. The device's technology and ongoing improvements based on trial results and FDA feedback could position it favorably in the healthcare market.
知U的推出爲市場提供了重要的機遇，其非侵入式監測技術適合連續使用，爲糖尿病管理提供了潛在的飛躍。設備的技術和基於試驗結果和FDA反饋的持續改進可能會在醫療市場上處於有利地位。
Risks:
風險：
The ongoing need for additional clinical trials, regulatory approvals, and subsequent rounds of funding to sustain operations poses considerable risk, particularly as the technology has yet to be commercialized and is still dependent on investor confidence and regulatory clearance.
持續需要額外的臨床試驗、監管批准和後續的資金支持以維持運營，這存在相當大的風險，特別是由於該技術尚未商業化，仍然依賴於投資者信心和監管審批。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。